Wyeth news from FiercePharma
NewsMerck to cut 1,200 sales reps
The axeman cometh to Merck's sales force. The drugmaker plans to lop off about 15 percent in the sales ranks, or 1,200 jobs. The fact that it's not alone in trimming back on reps--Wyeth just Read more...
Enbrel gets black-box infection warning
Enbrel's new black box is now official. Wyeth and Amgen have put the final touches on a Read more...
Wyeth to slash another 1,200 jobs
And the ax is falling again. Wyeth notified employees last Friday than another 1,200 jobs will be slashed from the payroll. That's on top of the Read more...
Lundbeck poaches CEO from Wyeth ranks
Wanted: CEO who can find a new "cash cow" to push a Danish drugmaker past impending patent expirations. Found: Ulf Wiinberg, lately of Wyeth, to take over Lundbeck. Soon to be ex-president Read more...
Wyeth discounts Pristiq for big sales push
Think the latest-and-greatest drug would naturally be the most expensive? Think again. Now that its Pristiq antidepressant is Read more...
SPOTLIGHT: Wyeth sales boosted by Enbrel
Despite major erosion in sales of its heartburn blockbuster Protonix, Wyeth managed to beat Wall Street's expectations for first-quarter earnings, posting a $1.2 billion profit on a 6 percent Read more...
Strategy execs advise Big Pharma
How might drugmakers navigate the rocky waters of generic competition, cautious regulators, safety scandals, globalization, and so on? Seek help with the itinerary from an expert, perhaps. At least Read more...
1,200 Wyeth reps out of work
Don't tell these 1,200 Wyeth sales reps to have a nice weekend. They got pink slips on Wednesday, their jobs eliminated in the drugmaker's Read more...
CFOs are pharma's new power players
Who's pharma's power forward these days? The CFO. Or so concludes Ernst & Young after slicing and dicing two global surveys. As companies shift focus from driving sales growth to managing Read more...
BMS chief nabs $10 million raise
Why is Jim Cornelius (photo) smiling? His big promotion to permanent CEO of Bristol-Myers Squibb Read more...
| Press ReleasesPRESS RELEASE: Raven biotechnologies and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies Raven biotechnologies and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies SOUTH SAN FRANCISCO, Calif., Dec. 6 -- Raven biotechnologies, inc., a privately held company Read more... PRESS RELEASE: Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Children's Dimetapp Cold & Chest Congestion -- Dosage Cup Being Replaced, No Read more... PRESS RELEASE: Wyeth Jury Awards $99 Million Punitive Damages Wyeth Jury Awards $99 Million Punitive Damages MADISON, N.J., Oct. 15 -- Wyeth confirmed today that it will appeal the verdict in the Scofield, Rowatt and Forrester v. Wyeth cases in the Second Read more... PRESS RELEASE: Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo COLLEGEVILLE, Pa., Oct. 15 -- Wyeth Pharmaceuticals, a Read more... PRESS RELEASE: Wyeth Acquires Haptogen to Boost Biotechnology Drug Discovery Wyeth Acquires Haptogen to Boost Biotechnology Drug Discovery COLLEGEVILLE, Pa., Oct. 5 -- Wyeth Pharmaceuticals, a division of Wyeth, announced today the signing of a definitive agreement under Read more... |
Get more Wyeth coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight